



**Aromics**  
APPLIED RESEARCH USING OMIC SCIENCES

## Aromics as Snapshot

Applied Research using **Omic Sciences** is a development stage pharmaceutical company focused on developing novel first in class small molecules for the treatment of cancer. Current pipeline includes compounds against hard to treat and rare oncology conditions such as malignant mesothelioma and small lung cancer.

AROMICS advanced understanding of the biology of the tumor and the response to current treatments has resulted in a novel therapeutic approach for the treatment of niche cancer disorders. Compounds have been successfully tested in various cancer models, including chemotherapy resistant models. The NCE's specifically target the thymidylate synthase and dihydrofolate reductase enzyme by an unprecedented mechanism regulating post-transcriptional mechanism and resulting in the silencing of the protein expression. Induction of autophagy, mediated by the repression of Wnt/ $\beta$ -catenin system is also a hallmark of these compounds. For scientific papers, see the company website.

## Malignant Mesothelioma

Orally and/or i.v. administered, NAX035 is a preclinical stage asset undergoing regulatory path up to phase IB trial in patients with refractory malignant mesothelioma

Preclinical profile of the compound shows good efficacy even in refractory tumors, adequate safety and toxicology profile. The regulatory preclinical will be finished at Q4 2016. The first clinical trial is expected to start in 2Q2017.

## Other cancer types

Applied orally and/or I.V., NAX035 is a first candidate form a family of pre-clinical stage assets being developed for the treatment of cancer malignancies such as lung, ovarian, breast and colon cancer, with in vitro and in vivo efficacy.

## Financing

AROMICS is completing a first seed capital round foreseen in 1Q 2016, and advancing on a first early stage round for NAX035 clinical development

## Chemistry

NAX035 is a first-in-class molecule resulted from a rational chemical modification of Berberine, resulting in a potent and selective anticancer agent.

## Intellectual Property

Compounds are the result of specific co-development agreements with a chemistry-driven Italian company Naxospharma. The compounds are protected under issued patents and patent applications covering major markets, and exclusively licensed to Aromics. The company continuously updates and expands its intellectual property estate in accordance with its life cycle management policy.

## Partnering

AROMICS is looking for pharma partners for its most advanced development programs during 2016.



Filling the gap in drug discovery  
...improving patients' treatment  
...assuring quality of life

### THERAPEUTIC FOCUS

Small molecules targeting post-transcriptional events, resulting in protein expression abrogation as major putative effect. Useful in cancer.

### FOUNDED

In 2005, as a start-up devoted to drug development, in Barcelona, Spain.

### MANAGEMENT

Mr. Narcis Clavell, Chairman  
Dr. Carmen Plasencia, CEO

### BOARD OF DIRECTORS

Carmen Plasencia, Narcís Clavell,  
Inmaculada Dalmau.

### LOCATION

#### Headquarters:

C/Víctor Pradera, 45  
08940, Cornellà de Llobregat  
Barcelona, SPAIN

#### Laboratory Facilities:

Barcelona Science Park  
c/ Baldriri Reixac 15-21  
Helix Building, 2<sup>nd</sup> Floor, Lab 03  
08028 Barcelona, SPAIN

### FOR FURTHER INFORMATION

Carmen Plasencia, CEO  
e-mail: info@aromics.es

COMPOUND	INDICATION	IN VITRO PoC	IN VIVO PoC	PRECLINICAL	CLINICAL PHASE IB	CLINICAL PHASE II	PARTNERSHIP
NAX035	Malignant Mesothelioma	[Progress bar]					
	Small cell lung cancer	[Progress bar]					
	Non-small cell lung cancer	[Progress bar]					
	CDDP-resistant Ovarian Cancer	[Progress bar]					
NAX014	Refractory Her2+ Breast cancer	[Progress bar]					